Originally posted on DRUG REGULATORY AFFAIRS INTERNATIONAL:
October 31, 2015 — 2:22 AM IST,
The Pfizer Ltd. research and development plant in Dalian, China.
Bernardo De Niz/Bloomberg
A Pfizer Inc. plant in China that was being inspected by Food and Drug Administration regulators in order to ship drugs to the U.S. kept a second set of quality and manufacturing records that didn’t match official ones, according to an FDA review of the facility.
read
/////
Filed under: Uncategorized